<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336413</url>
  </required_header>
  <id_info>
    <org_study_id>B4603-I</org_study_id>
    <nct_id>NCT01336413</nct_id>
    <nct_alias>NCT01327131</nct_alias>
  </id_info>
  <brief_title>Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans</brief_title>
  <official_title>Neuroactive Steroids and TBI in OEF/OIF Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: Mild traumatic brain injury (TBI) is extremely common among Operation Enduring
      Freedom/Operation Iraqi Freedom (OEF/OIF) era Veterans. Mild TBI is frequently accompanied by
      post-traumatic stress disorder (PTSD) and depression symptoms, co-occurring disorders that
      contribute to increased disability and decreased quality of life. Neuroactive steroids (NS)
      represent promising pharmacological candidates for intervention for these diverse symptom
      domains, since a number of these molecules demonstrate pronounced neuroprotective and
      neurotrophic properties. The NS pregnenolone (PREG) is a logical therapeutic option, since it
      enhances learning and memory and also increases myelination in rodent models. Further,
      decreases in PREG have been associated with depressive symptoms, and PREG is also metabolized
      to allopregnanolone (ALLO), an anxiolytic downstream NS that is decreased in PTSD. ALLO also
      enhances neurogenesis in rodents. The investigators thus propose an randomized controlled
      trial (RCT) in OEF/OIF era Veterans with mild TBI.

      Methodology: The design of this study will be randomized, placebo-controlled, double-blind.
      Trial duration will be 10 weeks, consisting of a 2-week placebo lead-in period for all
      subjects, followed by 8 weeks of treatment with either pregnenolone or placebo. The primary
      cognitive outcome measure will be executive functioning (as assessed by the Tower of London
      test), and the primary behavioral outcome measure will be PTSD Cluster D symptoms (as
      assessed by the Clinician-Administered PTSD Scale, CAPS). The investigators will also
      determine if PREG administration in OEF/OIF Veterans with mild TBI increases downstream ALLO
      and/or other GABAergic NS levels, and the investigators will identify the specific metabolism
      profile of PREG following eight weeks of treatment with this neurosteroid.

      Anticipated Findings: The investigators hypothesize that treatment with PREG in OEF/OIF era
      Veterans with mild TBI will significantly improve executive functioning compared to the
      placebo condition. The investigators also predict that treatment with PREG will decrease
      Cluster D PTSD symptoms compared to treatment with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: Mild traumatic brain injury (TBI) is extremely common among OEF/OIF (Operation
      Enduring Freedom/Operation Iraqi Freedom) era Veterans. Mild TBI is frequently accompanied by
      post-traumatic stress disorder (PTSD) and depression symptoms, co-occurring disorders that
      contribute to increased disability and decreased quality of life. Neuroactive steroids (NS)
      represent promising pharmacological candidates for intervention for these diverse symptom
      domains, since a number of these molecules demonstrate pronounced neuroprotective and
      neurotrophic properties. The NS pregnenolone (PREG) is a logical therapeutic option, since it
      enhances learning and memory and also increases myelination in rodent models. Further,
      decreases in PREG have been associated with depressive symptoms, and PREG is also metabolized
      to allopregnanolone (ALLO), an anxiolytic downstream NS that is decreased in PTSD. ALLO also
      enhances neurogenesis in rodents. The investigators thus propose an RCT in OEF/OIF era
      Veterans with mild TBI.

      Methodology: The design of this study will be randomized, placebo-controlled, double-blind.
      Trial duration will be 10 weeks, consisting of a 2-week placebo lead-in period for all
      subjects, followed by 8 weeks of treatment with either pregnenolone or placebo. The primary
      cognitive outcome measure will be executive functioning (as assessed by the Tower of London
      test), and the primary behavioral outcome measure will be PTSD Cluster D symptoms (as
      assessed by the Clinician-Administered PTSD Scale, CAPS). The investigators will also
      determine if PREG administration in OEF/OIF Veterans with mild TBI increases downstream ALLO
      and/or other GABAergic NS levels, and the investigators will identify the specific metabolism
      profile of PREG following eight weeks of treatment with this neurosteroid. A subset of
      patients will also receive pre/post neuroimaging (functional magnetic resonance imaging
      [fMRI], diffusion tensor imaging [DTI], and quantitative susceptibility
      mapping/susceptibility tensor imaging [QSM/STI]).

      Anticipated Findings: The investigators hypothesize that treatment with PREG in OEF/OIF era
      Veterans with mild TBI will significantly improve executive functioning compared to the
      placebo condition. The investigators also predict that treatment with PREG will decrease
      Cluster D PTSD symptoms compared to treatment with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAPS (Cluster D Symptoms) - PRIMARY BEHAVIORAL OUTCOME MEASURE</measure>
    <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
    <description>The CAPS-IV criterion D is defined by persistent symptoms of increasing arousal (not present before the trauma), indicated by at least two of the following: difficulty falling or staying asleep, irritability or outbursts of anger, difficulty concentrating, hyper-vigilance, and exaggerated startle response There are two scales, frequency and intensity. Frequency scores range from 0 = &quot;none of the time&quot; to 4 = &quot;most or all of the time&quot; and intensity scores range from 0 = &quot;none&quot; to 4 = &quot;extreme.&quot; Severity scores are calculated from the sum of frequency and intensity scores. Five items are included in criterion D, thus the range of severity scores is 0-45. Higher scores are indicative of more symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tower of London (Subscale Test of BAC) - PRIMARY COGNITIVE OUTCOME MEASURE</measure>
    <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
    <description>Subscale test asking subjects to determine the minimum number of moves that will be required to make convert one image of colored balls on pegs into a second different image. The test administers 20 items/images, with 2 additional items if all of the first 20 are answered correctly. Thus, scores range from 0-22, with lower scores representing greater impairment. Raw scores are converted to z scores that generally range from -3 to 3, with lower scores again representing greater impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
    <description>21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Scores range from 0 (no depression) to 63 (severe depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAC Composite</measure>
    <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
    <description>Composite z scores (allowing comparison from week 2 to week 10) to assess cognitive changes. The BAC includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed. z scores are calculated from composite scores. Higher z scores are indicative of better cognitive performance, lower z scores are indicative of lower cognitive performance. Range of z scores anticipated to be between -3 and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAPS Total Scores</measure>
    <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
    <description>Mean scores in posttraumatic stress disorder symptoms. Scores may range from 0 (no symptoms) to 136 (severe symptoms; score of 136 is based on the first 17 CAPS items administered). A reduced CAPS score indicates a reduction in (improvement) PTSD symptoms, while and increase in CAPS score indicates an increase (worsening) in PTSD symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connor-Davidson Resilience Scale (CD-RISC)</measure>
    <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
    <description>The CD-RISC was developed and tested as (i) a measure of degree of resilience, (ii) as a predictor of outcome to treatment with medication or psychotherapy, stress management and resilience-building, (iii) as a marker of progress during treatment, and (iv) as a marker of biological changes in the brain. The scale comprises 25 items, each rated on a 5-point scale (0-4) for a total range of 0-100, with higher scores reflecting greater resilience.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional Magnetic Resonance Imaging (Exploratory Neuroimaging Outcome)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Functional Magnetic Resonance Imaging (fMRI) to assess possible functional brain changes related to attention and emotion circuits associated with the intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Diffusion Tensor Imaging (Exploratory Neuroimaging Outcome)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Diffusion Tensor Imaging (DTI) to assess possible white matter brain changes associated with intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative Susceptibility Mapping/Susceptibility Tensor Imaging (Exploratory Neuroimaging Outcome)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Quantitative Susceptibility Mapping/Susceptibility Tensor Imaging (QSM/STI) to assess possible myelin brain changes related to the intervention.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregnenolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnenolone</intervention_name>
    <description>Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same as active comparator, except placebo dispensed.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-55 years of age, any ethnic group, either sex

          -  History of mild TBI since 2001

          -  The investigators will adhere to the operational definition of mild TBI suggested by
             the World Health Organization Task Force (Holm et al 2005), with the exception of
             Glasgow Coma Scale score criteria (not available for these subjects): a.) One or more
             of the following: confusion or disorientation, loss of consciousness for 30 minutes or
             less, post-traumatic amnesia for less than 24 hours, and/or other transient
             neurological abnormalities such as focal signs, seizure, and intracranial lesion not
             requiring surgery; Glasgow Coma Scale (GCS) score of 13-15 after 30 minutes
             post-injury or later upon presentation for health care (GCS unavailable). This WHO
             diagnostic definition of mild TBI is also consistent with the CDC Report to Congress
             on Mild TBI in the United States, September 2003 (specifically, altered consciousness
             attributable to the head injury [=transient confusion, disorientation or impaired
             consciousness] or self reported loss of consciousness lasting 30 minutes or less).

          -  Ability to participate fully in the informed consent process.

          -  No anticipated need to alter psychiatric medications for the 10-week duration of the
             study. Since this study is adjunctive to treatment-as-usual, patients will not be
             tapered from any psychiatric medications they may be receiving at enrollment.

          -  No changes in psychotropic or behavioral interventions during the study or in the 4
             weeks prior to study enrollment.

        Exclusion Criteria:

          -  For this pilot study, the investigators will diverge slightly from the above WHO
             definition of mild TBI and exclude patients who report a history of seizures for this
             investigation. Although no seizures have been reported to the FDA in relationship to
             pregnenolone use, pregnenolone could theoretically influence seizure threshold if
             metabolized to its sulfated derivative, which demonstrates negative modulatory actions
             at GABAA receptors. Since the preliminary data suggest that pregnenolone
             administration increases the GABAergic neuroactive steroid allopregnanolone five-fold,
             however, and since allopregnanolone demonstrates marked anticonvulsant activity in a
             number of animal seizure models, this theoretical risk may be small or non-existent.

          -  Subjects with current suicidal or homicidal ideation necessitating clinical
             intervention or representing an imminent concern.

          -  Concomitant medications for medical conditions will be addressed on a case-by-case
             base and determined if exclusionary.

          -  Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic
             disorder, or cognitive disorder due to a general medical condition other than TBI.

          -  Female patients who are pregnant or breast-feeding.

          -  Known allergy to study medication.

          -  Substance dependence or abuse (other than nicotine dependence), as determined by MINI
             assessment.

          -  Serious unstable medical illness. History of cerebrovascular accident, prostate,
             uterine or breast cancer.

          -  Use of oral contraceptives or other hormonal supplementation such as estrogen
             [although early studies suggested no effects on menstrual cycle, alterations in
             downstream metabolites of pregnenolone could theoretically impact efficacy of oral
             contraceptives and estrogen replacement].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Marx, MD MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durham VA Medical Center, Durham, NC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VA Medical Center, Durham, NC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <results_first_submitted>May 19, 2017</results_first_submitted>
  <results_first_submitted_qc>September 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2017</results_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain injuries, traumatic</keyword>
  <keyword>pregnenolone</keyword>
  <keyword>Veteran</keyword>
  <keyword>OEF/OIF</keyword>
  <keyword>neurosteroid</keyword>
  <keyword>allopregnanolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pregnenolone</title>
          <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Same as active comparator, except placebo dispensed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pregnenolone</title>
          <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Same as active comparator, except placebo dispensed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.74" spread="5.40"/>
                    <measurement group_id="B2" value="35.04" spread="6.75"/>
                    <measurement group_id="B3" value="33.87" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CAPS (Cluster D Symptoms) - PRIMARY BEHAVIORAL OUTCOME MEASURE</title>
        <description>The CAPS-IV criterion D is defined by persistent symptoms of increasing arousal (not present before the trauma), indicated by at least two of the following: difficulty falling or staying asleep, irritability or outbursts of anger, difficulty concentrating, hyper-vigilance, and exaggerated startle response There are two scales, frequency and intensity. Frequency scores range from 0 = &quot;none of the time&quot; to 4 = &quot;most or all of the time&quot; and intensity scores range from 0 = &quot;none&quot; to 4 = &quot;extreme.&quot; Severity scores are calculated from the sum of frequency and intensity scores. Five items are included in criterion D, thus the range of severity scores is 0-45. Higher scores are indicative of more symptoms.</description>
        <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
        <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Same as active comparator, except placebo dispensed.</description>
          </group>
        </group_list>
        <measure>
          <title>CAPS (Cluster D Symptoms) - PRIMARY BEHAVIORAL OUTCOME MEASURE</title>
          <description>The CAPS-IV criterion D is defined by persistent symptoms of increasing arousal (not present before the trauma), indicated by at least two of the following: difficulty falling or staying asleep, irritability or outbursts of anger, difficulty concentrating, hyper-vigilance, and exaggerated startle response There are two scales, frequency and intensity. Frequency scores range from 0 = &quot;none of the time&quot; to 4 = &quot;most or all of the time&quot; and intensity scores range from 0 = &quot;none&quot; to 4 = &quot;extreme.&quot; Severity scores are calculated from the sum of frequency and intensity scores. Five items are included in criterion D, thus the range of severity scores is 0-45. Higher scores are indicative of more symptoms.</description>
          <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.88" spread="1.51"/>
                    <measurement group_id="O2" value="12.89" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.23" spread="1.63"/>
                    <measurement group_id="O2" value="10.89" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" spread="1.46"/>
                    <measurement group_id="O2" value="12.24" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tower of London (Subscale Test of BAC) - PRIMARY COGNITIVE OUTCOME MEASURE</title>
        <description>Subscale test asking subjects to determine the minimum number of moves that will be required to make convert one image of colored balls on pegs into a second different image. The test administers 20 items/images, with 2 additional items if all of the first 20 are answered correctly. Thus, scores range from 0-22, with lower scores representing greater impairment. Raw scores are converted to z scores that generally range from -3 to 3, with lower scores again representing greater impairment.</description>
        <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
        <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Same as active comparator, except placebo dispensed.</description>
          </group>
        </group_list>
        <measure>
          <title>Tower of London (Subscale Test of BAC) - PRIMARY COGNITIVE OUTCOME MEASURE</title>
          <description>Subscale test asking subjects to determine the minimum number of moves that will be required to make convert one image of colored balls on pegs into a second different image. The test administers 20 items/images, with 2 additional items if all of the first 20 are answered correctly. Thus, scores range from 0-22, with lower scores representing greater impairment. Raw scores are converted to z scores that generally range from -3 to 3, with lower scores again representing greater impairment.</description>
          <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
          <units>z Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.14"/>
                    <measurement group_id="O2" value="-0.17" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.15"/>
                    <measurement group_id="O2" value="0.14" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.17"/>
                    <measurement group_id="O2" value="0.43" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory-II (BDI-II)</title>
        <description>21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Scores range from 0 (no depression) to 63 (severe depression).</description>
        <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
        <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Same as active comparator, except placebo dispensed.</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory-II (BDI-II)</title>
          <description>21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Scores range from 0 (no depression) to 63 (severe depression).</description>
          <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
          <units>Total Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27" spread="1.15"/>
                    <measurement group_id="O2" value="10.56" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.42" spread="1.24"/>
                    <measurement group_id="O2" value="8.44" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" spread="0.87"/>
                    <measurement group_id="O2" value="8.88" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAC Composite</title>
        <description>Composite z scores (allowing comparison from week 2 to week 10) to assess cognitive changes. The BAC includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed. z scores are calculated from composite scores. Higher z scores are indicative of better cognitive performance, lower z scores are indicative of lower cognitive performance. Range of z scores anticipated to be between -3 and 3.</description>
        <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
        <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Same as active comparator, except placebo dispensed.</description>
          </group>
        </group_list>
        <measure>
          <title>BAC Composite</title>
          <description>Composite z scores (allowing comparison from week 2 to week 10) to assess cognitive changes. The BAC includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed. z scores are calculated from composite scores. Higher z scores are indicative of better cognitive performance, lower z scores are indicative of lower cognitive performance. Range of z scores anticipated to be between -3 and 3.</description>
          <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
          <units>Composite z Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.22"/>
                    <measurement group_id="O2" value="-0.59" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.20"/>
                    <measurement group_id="O2" value="-0.10" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.26"/>
                    <measurement group_id="O2" value="0.17" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CAPS Total Scores</title>
        <description>Mean scores in posttraumatic stress disorder symptoms. Scores may range from 0 (no symptoms) to 136 (severe symptoms; score of 136 is based on the first 17 CAPS items administered). A reduced CAPS score indicates a reduction in (improvement) PTSD symptoms, while and increase in CAPS score indicates an increase (worsening) in PTSD symptoms.</description>
        <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
        <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Same as active comparator, except placebo dispensed.</description>
          </group>
        </group_list>
        <measure>
          <title>CAPS Total Scores</title>
          <description>Mean scores in posttraumatic stress disorder symptoms. Scores may range from 0 (no symptoms) to 136 (severe symptoms; score of 136 is based on the first 17 CAPS items administered). A reduced CAPS score indicates a reduction in (improvement) PTSD symptoms, while and increase in CAPS score indicates an increase (worsening) in PTSD symptoms.</description>
          <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
          <units>Total Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.04" spread="4.02"/>
                    <measurement group_id="O2" value="33.33" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.65" spread="3.52"/>
                    <measurement group_id="O2" value="26.22" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.83" spread="4.04"/>
                    <measurement group_id="O2" value="27.47" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Connor-Davidson Resilience Scale (CD-RISC)</title>
        <description>The CD-RISC was developed and tested as (i) a measure of degree of resilience, (ii) as a predictor of outcome to treatment with medication or psychotherapy, stress management and resilience-building, (iii) as a marker of progress during treatment, and (iv) as a marker of biological changes in the brain. The scale comprises 25 items, each rated on a 5-point scale (0-4) for a total range of 0-100, with higher scores reflecting greater resilience.</description>
        <time_frame>Baseline, 4 Weeks, and 8 Weeks</time_frame>
        <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Same as active comparator, except placebo dispensed.</description>
          </group>
        </group_list>
        <measure>
          <title>Connor-Davidson Resilience Scale (CD-RISC)</title>
          <description>The CD-RISC was developed and tested as (i) a measure of degree of resilience, (ii) as a predictor of outcome to treatment with medication or psychotherapy, stress management and resilience-building, (iii) as a marker of progress during treatment, and (iv) as a marker of biological changes in the brain. The scale comprises 25 items, each rated on a 5-point scale (0-4) for a total range of 0-100, with higher scores reflecting greater resilience.</description>
          <population>3 subjects in Arm 1, and 1 subject in Arm 2, withdrew prior to the final visit of the study.</population>
          <units>Total Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.19" spread="2.38"/>
                    <measurement group_id="O2" value="69.06" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.73" spread="2.45"/>
                    <measurement group_id="O2" value="72.22" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.13" spread="2.62"/>
                    <measurement group_id="O2" value="73.11" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Functional Magnetic Resonance Imaging (Exploratory Neuroimaging Outcome)</title>
        <description>Functional Magnetic Resonance Imaging (fMRI) to assess possible functional brain changes related to attention and emotion circuits associated with the intervention.</description>
        <time_frame>10 weeks</time_frame>
        <posting_date>02/2018</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Diffusion Tensor Imaging (Exploratory Neuroimaging Outcome)</title>
        <description>Diffusion Tensor Imaging (DTI) to assess possible white matter brain changes associated with intervention.</description>
        <time_frame>10 weeks</time_frame>
        <posting_date>02/2018</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quantitative Susceptibility Mapping/Susceptibility Tensor Imaging (Exploratory Neuroimaging Outcome)</title>
        <description>Quantitative Susceptibility Mapping/Susceptibility Tensor Imaging (QSM/STI) to assess possible myelin brain changes related to the intervention.</description>
        <time_frame>10 weeks</time_frame>
        <posting_date>02/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pregnenolone</title>
          <description>Pregnenolone: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Same as active comparator, except placebo dispensed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="30" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E2" events="26" subjects_affected="10" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Irritabilty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Decreased Motor Activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Increased Motor Activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain/Stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Muscle Pain/Stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christine E. Marx, MD MA</name_or_title>
      <organization>VHA Durham</organization>
      <phone>9192860411 ext 3626</phone>
      <email>christine.marx@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

